1921
Volume 92, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Artemisinin-based combination therapies (ACTs) are currently considered the first-line treatments for uncomplicated malaria. Among these, artemether-lumefantrine (AL) has been the most widely prescribed ACT in sub-Saharan Africa. Recent clinical trials conducted in sub-Saharan Africa have shown that dihydroartemisinin-piperaquine (DP), a most recent ACT, may have a longer post-treatment prophylactic period and post-treatment infection period (duration of gametocyte carriage) than AL. Using epidemiological and clinical data on the efficacy of AL and DP, we developed and parameterized a mathematical transmission model that we used to compare the population-level impact of AL and DP for reducing malaria transmission in sub-Saharan Africa. Our results showed that DP is likely to more effectively reduce malaria incidence of clinical episodes than AL. However in low transmission areas, DP and AL are likely to be equally effective in reducing malaria prevalence. The predictions of our model were shown to be robust to the empirical uncertainty summarizing the epidemiological parameters. DP should be considered as a replacement for AL as first-line treatment of uncomplicated malaria in highly endemic communities. To optimize the effectiveness of ACTs, it is necessary to tailor treatment policies to the transmission intensity in different settings.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0490
2015-03-04
2017-11-18
Loading full text...

Full text loading...

/deliver/fulltext/14761645/92/3/555.html?itemId=/content/journals/10.4269/ajtmh.14-0490&mimeType=html&fmt=ahah

References

  1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI, , 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214217.[Crossref]
  2. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD, , 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413431.[Crossref]
  3. O'Meara WP, Mangeni JN, Steketee R, Greenwood B, , 2010. Changes in the burden of malaria in sub-Saharan Africa. Lancet Infect Dis 10: 545555.[Crossref]
  4. Nyarango PM, Gebremeskel T, Mebrahtu G, Mufunda J, Abdulmumini U, Ogbamariam A, Kosia A, Gebremichael A, Gunawardena D, Ghebrat Y, Okbaldet Y, , 2006. A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. Malar J 5: 33.[Crossref]
  5. Fegan GW, Noor AM, Akhwale WS, Cousens S, Snow RW, , 2007. Effect of expanded insecticide-treated bed net coverage on child survival in rural Kenya: a longitudinal study. Lancet 370: 10351039.[Crossref]
  6. Barnes KI, Chanda P, Ab Barnabas G, , 2009. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar J 8 (Suppl 1): S8.[Crossref]
  7. White NJ, , 2004. Antimalarial drug resistance. J Clin Invest 113: 10841092.[Crossref]
  8. Beeson JG, , ed., 2011. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 8: e1001119.[Crossref]
  9. Thwing J, Eisele TP, Steketee RW, , 2011. Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. BMC Public Health 11 (Suppl 3): S14.[Crossref]
  10. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, , 2004. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363: 917.[Crossref]
  11. Sawa P, Shekalaghe SA, Drakeley CJ, Sutherland CJ, Mweresa CK, Baidjoe AY, Manjurano A, Kavishe RA, Beshir KB, Yussuf RU, Omar SA, Hermsen CC, Okell L, Schallig HD, Sauerwein RW, Hallett RL, Bousema T, , 2013. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 207: 16371645.[Crossref]
  12. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G, , 2009. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 49: 16291637.[Crossref]
  13. Agarwal A, McMorrow M, Onyango P, Otieno K, Odero C, Williamson J, Kariuki S, Kachur SP, Slutsker L, Desai M, , 2013. A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya. Malar J 12: 254.[Crossref]
  14. Wanzira H, Kakuru A, Arinaitwe E, Bigira V, Muhindo MK, Conrad M, Rosenthal PJ, Kamya MR, Tappero JW, Dorsey G, , 2014. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis 59: 509516.[Crossref]
  15. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, Nambozi M, Valéa I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D'Alessandro U, , 2009. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomized, non-inferiority trial. PLoS ONE 4: e7871.[Crossref]
  16. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S, , 2013. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis 207: 16461654.[Crossref]
  17. Abay S, , 2013. Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis. Parasit Vectors 6: 278.[Crossref]
  18. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, Bousema T, Drakeley CJ, Ferguson NM, Basáñez M-G, Ghani AC, , 2010. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 7: 17.[Crossref]
  19. Marino S, Hogue IB, Ray CJ, Kirschner DE, , 2008. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol 254: 178196.[Crossref]
  20. Okell LC, Drakeley CJ, Bousema T, Whitty CJM, Ghani AC, , 2008. Modeling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med 5: e226; discussion e226.[Crossref]
  21. Smith DL, McKenzie FE, Snow RW, Hay SI, , 2007. Revisiting the basic reproductive number for malaria and its implications for malaria control. PLoS Biol 5: e42.[Crossref]
  22. Woolhouse ME, Dye C, Etard JF, Smith T, Charlwood JD, Garnett GP, Hagan P, Hii JL, Ndhlovu PD, Quinnell RJ, Watts CH, Chandiwana SK, Anderson RM, , 1997. Heterogeneities in the transmission of infectious agents: implications for the design of control programs. Proc Natl Acad Sci USA 94: 338342.[Crossref]
  23. Bousema T, Drakeley C, Gesase S, Hashim R, Magesa S, Mosha F, Otieno S, Carneiro I, Cox J, Msuya E, Kleinschmidt I, Maxwell C, Greenwood B, Riley E, Sauerwein R, Chandramohan D, Gosling R, , 2010. Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis 201: 17641774.[Crossref]
  24. Smith DL, Dushoff J, Snow RW, Hay SI, , 2005. The entomological inoculation rate and Plasmodium falciparum infection in African children. Nature 438: 492495.[Crossref]
  25. Sutanto I, Suprijanto S, Kosasih A, Dahlan MS, Syafruddin D, Kusriastuti R, Hawley WA, Lobo NF, Ter Kuile FO, , 2013. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in south Sumatra, western Indonesia: an open-label, randomized, controlled trial. Clin Infect Dis 56: 685693.[Crossref]
  26. Boni MF, Smith DL, Laxminarayan R, , 2008. Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA 105: 1421614221.[Crossref]
  27. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han K-T, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ, , 2014. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371: 411423.[Crossref]
  28. Saunders DL, Vanachayangkul P, Lon C, , 2014. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 371: 484485.[Crossref]
  29. Utzinger J, N'Goran EK, N’Dri A, Lengeler C, Shuhua X, Tanner M, , 2000. Oral artemether for prevention of Schistosoma mansoni infection: randomized controlled trial. Lancet 355: 13201325.[Crossref]
  30. Sokhna C, Le Hesran J-Y, Mbaye PA, Akiana J, Camara P, Diop M, Ly A, Druilhe P, , 2004. Increase of malaria attacks among children presenting concomitant infection by Schistosoma mansoni in Senegal. Malar J 3: 43.[Crossref]
  31. Sangweme DT, Midzi N, Zinyowera-Mutapuri S, Mduluza T, Diener-West M, Kumar N, , 2010. Impact of schistosome infection on Plasmodium falciparum malariometric indices and immune correlates in school age children in Burma Valley, Zimbabwe. PLoS Negl Trop Dis 4: e882.[Crossref]
  32. Druilhe P, Tall A, Sokhna C, , 2005. Worms can worsen malaria: towards a new means to roll back malaria? Trends Parasitol 21: 359362.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0490
Loading
/content/journals/10.4269/ajtmh.14-0490
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 05 Aug 2014
  • Accepted : 22 Oct 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error